1. Home
  2. CCIX vs LRMR Comparison

CCIX vs LRMR Comparison

Compare CCIX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCIX
  • LRMR
  • Stock Information
  • Founded
  • CCIX 2023
  • LRMR N/A
  • Country
  • CCIX United States
  • LRMR United States
  • Employees
  • CCIX N/A
  • LRMR N/A
  • Industry
  • CCIX
  • LRMR Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCIX
  • LRMR Health Care
  • Exchange
  • CCIX Nasdaq
  • LRMR Nasdaq
  • Market Cap
  • CCIX 386.4M
  • LRMR 309.8M
  • IPO Year
  • CCIX 2024
  • LRMR N/A
  • Fundamental
  • Price
  • CCIX $10.49
  • LRMR $3.98
  • Analyst Decision
  • CCIX
  • LRMR Strong Buy
  • Analyst Count
  • CCIX 0
  • LRMR 8
  • Target Price
  • CCIX N/A
  • LRMR $17.88
  • AVG Volume (30 Days)
  • CCIX 45.6K
  • LRMR 1.3M
  • Earning Date
  • CCIX 11-07-2013
  • LRMR 10-29-2025
  • Dividend Yield
  • CCIX N/A
  • LRMR N/A
  • EPS Growth
  • CCIX N/A
  • LRMR N/A
  • EPS
  • CCIX 0.28
  • LRMR N/A
  • Revenue
  • CCIX N/A
  • LRMR N/A
  • Revenue This Year
  • CCIX N/A
  • LRMR N/A
  • Revenue Next Year
  • CCIX N/A
  • LRMR N/A
  • P/E Ratio
  • CCIX $37.07
  • LRMR N/A
  • Revenue Growth
  • CCIX N/A
  • LRMR N/A
  • 52 Week Low
  • CCIX $10.01
  • LRMR $1.61
  • 52 Week High
  • CCIX $11.66
  • LRMR $9.50
  • Technical
  • Relative Strength Index (RSI)
  • CCIX 39.67
  • LRMR 54.35
  • Support Level
  • CCIX $10.45
  • LRMR $3.78
  • Resistance Level
  • CCIX $10.58
  • LRMR $4.26
  • Average True Range (ATR)
  • CCIX 0.05
  • LRMR 0.27
  • MACD
  • CCIX -0.00
  • LRMR -0.00
  • Stochastic Oscillator
  • CCIX 38.46
  • LRMR 56.63

About CCIX Churchill Capital Corp IX Ordinary Shares

Churchill Capital Corp IX is a blank check company.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: